𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pramipexole versus ropinirole: Polysomnographic acute effects in restless legs syndrome

✍ Scribed by Mauro Manconi; Raffaele Ferri; Marco Zucconi; Alessandro Oldani; Laura Giarolli; Valentina Bottasini; Luigi Ferini-Strambi

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
661 KB
Volume
26
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Background: Pramipexole and ropinirole have become the first‐line treatment for restless legs syndrome. The aim of this study was to perform the first direct comparison between these two molecules in restless legs syndrome. Methods: A double‐blind, placebo‐controlled, double‐night and prospective investigation was carried out in 45 consecutive naïve patients with idiopathic restless legs syndrome. Each patient underwent two consecutive full‐night polysomnographies: the first baseline recording was performed without premedication and, before the second recording, first group received a single oral dose of 0.25 mg pramipexole, second group a single oral dose of 0.5 mg ropinirole, and the remaining patients received placebo.

Results and Discussion: Both dopamine agonists improved restless legs syndrome symptoms and markedly suppressed periodic leg movements during sleep compared to placebo, without significant differences between pramipexole and ropinirole. No significant side effects, except for mild morning nausea (2 patients treated with ropinirole, 3 with pramipexole, and 1 with placebo), were reported. © 2011 Movement Disorder Society

📜 SIMILAR VOLUMES

Ropinirole is effective in the long-term
Ropinirole is effective in the long-term management of restless legs syndrome: A randomized controlled trial
✍ Jacques Montplaisir; Jeff Karrasch; Jean Haan; Dieter Volc 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 302 KB 👁 1 views

## Abstract The objective of this study was to investigate the long‐term efficacy of ropinirole in patients with restless legs syndrome (RLS) and to assess the potential for relapse after the discontinuation of active treatment. Patients with primary RLS (n = 202) received single‐blind ropinirole f

Efficacy of pramipexole in restless legs
Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study)
✍ Wolfgang H. Oertel; Karin Stiasny-Kolster; Bettina Bergtholdt; Yngve Hallström; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Abstract We evaluated the efficacy of pramipexole versus placebo in restless legs syndrome (RLS) for 6 weeks. Overall, 345 patients were randomly assigned in a 1:2 ratio to receive either placebo (n = 115) or pramipexole (n = 230) with a starting dose of 0.125 mg/day. The dose was individually o

Ropinirole is effective in the treatment
Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study
✍ Arthur S. Walters; William G. Ondo; Tilman Dreykluft; Ron Grunstein; Daniel Lee; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 1 views

## Abstract Restless legs syndrome (RLS) is a neurological condition with significant impact on sleep and quality of life (QoL). This double‐blind, randomized, 12‐week, multinational study compared the efficacy and safety of ropinirole and placebo in RLS. In total, 267 outpatients with moderate‐to‐